CCO Volker Hirsch sees "bright and ambitious future" for Medicines Discovery Catapult

26 October 2022
volker_hirsch_medicines_discovery_catapult_large

German-born UK resident Volker Hirsch has joined the Medicines Discovery Catapult (MDC) as chief commercial officer.

His brief is to direct the UK government-backed agency’s activity into impactful collaborative programs and investments, and drive further growth within the medicines discovery community.

"We will continue to identify more opportunities to strengthen the UK's position as a world leader in medicines discovery through impact investment"

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Today's issue

Company Spotlight





More Features in Biotechnology